Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: The infusion of mesenchymal stem cells post-treatment reduces hematopoietic toxicity and promotes hematopoietic reconstitution

Current Pharmaceutical Biotechnology

Volumn 14, Issue 9, 2013, Pages 842-848

  Fouillard, Loic ^a   Francois, Sabine ^b,e   Bouchet, Sandrine ^b   Bensidhoum, Morad ^c   Elm'selmi, Abdelatif ^d   Chapel, Alain ^c,e  

^a CENTRE HOSPITALIER RENÉ DUBOS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Ecole de Biologie Industrielle   (France)

^e INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

Acute myeloid leukemia; Bone marrow microenvironment; Chemo radiotherapy; Engraftment and haematopoietic recovery; Hematopoietic stem cells transplantation; Mesenchymal stem cells; Stromal derived factor 1 (SDF 1)

Indexed keywords

CHEMOTACTIC FACTOR; MESSENGER RNA; STROMA DERIVED FACTOR 1; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; CD45 ANTIGEN; ENDOGLIN; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL THERAPY; CHEMOTHERAPY; CLINICAL ARTICLE; COLONY FORMING UNIT FIBROBLAST; FEMALE; FIBROBLAST; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROENVIRONMENT; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ACUTE MYELOBLASTIC LEUKEMIA; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEMORADIOTHERAPY; COLONY FORMING UNIT F; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; LEUKEMIA REMISSION;

CELL- AND TISSUE-BASED THERAPY; CHEMOKINE CXCL12; CHEMORADIOTHERAPY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMAL CELLS; RNA, MESSENGER;

EID: 84893453345     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201014666131227120222     Document Type: Article

References (16)

1. Galotto, M.; Berisso, G.; Delfino, L, Podesta, Ottaggio, M. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp. Hematol., 1999, 27 (9), 1460-1466.
2. Roingeard, F.; Binet, C.; Lecron, J. C.; Truglio, D. Colombat, P. Cytokines released in vitro by stromal cells from autologous bone marrow transplant patients with lymphoid malignancy. Eur. J. Haematol., 1998, 61 (2), 100-108.
3. Domenech, J.; Roingeard.; F.; Herault, O.; Truglio. D, Desbois, I. Changes in the functional capacity of marrow stromal cells after autologous bone marrow transplantation. Leuk. Lymphoma., 1998, 29 (5-6), 533-546.
4. Koc, O. N.; Gerson, SL.; Cooper, BW.; Dyhouse, S. M. Haynesworth, S. E.; Caplan, A. I.; Lazarus, H. M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultureexpanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol., 2000, 18 (2), 307-316.
5. Ringden, O. Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation. Stem Cells Dev., 2009, 18 (9), 1243-1246.
6. Fouillard, L.; Chapel, A.; Bories, D.; Costa, J. M.; Rouard H, Hervé P, Gourmelon, P.; Thierry, D.; Lopez, M.; Gorin, N. C. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia, 2007, 21 (3), 568-570.
7. Le Blanc, K.; Samuelsson, H.; Gustafsson, B.; Remberger, M.; Sundberg, B. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 2007, 21 (8), 1733-1738.
8. Aiuti, A.; Webb, I. J, Bleul C.; Springer T.; Gutierrez-Ramos, J. C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med., 1997, 185 (2), 111-120.
9. Sharma, M.; Afrin, F.; Satija, N.; Tripathi, R. P.; Gangenahalli, G. U. Stromal-derived factor-1/CXCR4 signaling: indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev., 2011, 20 (2), 933-46.
10. Nagasawa.; T, Hirota, S.; Tachibana, K.; Takakura, N.; Nishikawa, S. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 1996, 382 (3), 635-638.
11. Carion, A.; Benboubker, L.; Herault, O.; Roingeard, F.; Degenne, M. Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells. Br. J. Haematol., 2003, 122 (6), 918-926.
12. Nervi, B.; Link, D. C.; DiPersio, J. F. Cytokines and hematopoietic stem cell mobilization. J. Cell. Biochem., 2006, 99 (3), 690-705.
13. Nasef, A.; Chapel, A.; Mazurier, C.; Francois, S.; Lopez, M. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr., 2007, 13 (4-5), 217-226.
14. Duhrsen, U.; Hossfeld, D. K. Stromal abnormalities in neoplastic bone marrow diseases. Ann. Hematol., 1996, 73 (2), 53-70.
15. Hodohara, K.; Fujii, N.; Yamamoto, N.; Kaushansky, K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood, 2000, 95 (3), 769-775.
16. Kim, C. H.; Broxmeyer, H. E. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood, 1998, 91 (1), 100-110.